Case Law Analysis
|Bombay High Court
Section 56(1) TM Act | Export Use Deemed Use in India; Pharma Marks Compared as Wholes Under Stricter Cadila Test : Bombay HC
The Bombay HC ordered rectification of LEFOXIN BIOX, holding it deceptively similar to Glaxo's 1956 LANOXIN mark under the stricter Cadila pharma test. Export sales constitute use in India under Section 56(1), but removal is deferred to December 31, 2026 for rebranding.